Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
Authors
Hongmei Jing
Zhiming Li (ORCID: https://orcid.org/0000-0001-9730-9917)
Yuqin Song (ORCID: https://orcid.org/0000-0001-5451-6481)
Jun Zhu (ORCID: https://orcid.org/0009-0006-1463-0363)
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
Hongmei Jing, Zhiming Li, Yuqin Song, Jun Zhu et al.
Citations
4 citations
Journal
Journal for ImmunoTherapy of Cancer
Topics
Lymphoma Diagnosis and Treatment
Field-Weighted Citation Impact (FWCI)
1.70
article
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial
Qingdao University (CN), Hebei Medical University (CN), University of Science and Technology of China (CN), Fujian Medical University (CN), Union Hospital (HK), Central South University (CN), Guiyang Medical University (CN), Harbin Medical University (CN), Sun Yat-sen University (CN), Guangxi Medical University (CN), Shanxi Medical University (CN), Shanghai Jiao Tong University (CN), Capital Medical University (CN), Dalian Medical University (CN), Jilin University (CN), Peking University (CN), Sichuan University (CN), Wenzhou Medical University (CN), Ruijin Hospital (CN), Tianjin Medical University Cancer Institute and Hospital (CN), First Affiliated Hospital of Xiamen University (CN), West China Hospital of Sichuan University (CN), Fudan University Shanghai Cancer Center (CN), Peking University Cancer Hospital (CN), Jilin Province Tumor Hospital (CN), Zhejiang Cancer Hospital (CN), Second Affiliated Hospital of Dalian Medical University (CN), Nanfang Hospital (CN), Guangdong Academy of Sciences (CN), Third Affiliated Hospital of Harbin Medical University (CN), The First People's Hospital of Changzhou (CN), Fourth Hospital of Hebei Medical University (CN), Affiliated Hospital of Guizhou Medical University (CN), Aerospace Center Hospital (CN), Hunan Cancer Hospital (CN), Affiliated Hospital of Qingdao University (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), First Hospital of Jilin University (CN), First Hospital of Shanxi Medical University (CN), Hainan General Hospital (CN), Anhui Provincial Hospital (CN), Twelfth Guangzhou City People's Hospital (CN), Peking University Third Hospital (CN), Guangdong Academy of Medical Sciences (CN), Sun Yat-sen University Cancer Center (CN), Shanghai Institute of Hematology (CN), Beijing Friendship Hospital (CN), Fujian Provincial Cancer Hospital (CN), Guangdong Provincial People's Hospital (CN), Changzhou Third People's Hospital (CN), Chongqing Cancer Hospital (CN), Tumor Hospital of Guangxi Medical University (CN), First Affiliated Hospital of Zhengzhou University (CN), 421 Hospital of PLA (CN), Second Affiliated Hospital of Zhejiang University (CN), Zhejiang Taizhou Hospital (CN), Xiangya Hospital Central South University (CN), Tongji Hospital (CN), Hubei Cancer Hospital (CN), Union Hospital (CN), Hangzhou Cancer Hospital (CN), First Affiliated Hospital Zhejiang University (CN), Huazhong University of Science and Technology (CN), Southern Medical University (CN), China Medical University (CN), Guangzhou Medical University (CN)
Funders
National Natural Science Foundation of China, Sun Yat-sen University, Natural Science Foundation of Guangdong Province, Sun Yat-sen University Cancer Center